We've published work in Analytical Chemistry on a serum-based blood test for lung cancer that reads the full Raman spectrum of a patient's blood rather than chasing a single biomarker. The appeal of this "data-first" approach is that it needs no predetermined target and only 5 microliters of serum, but is limited by the high similarity in chemical composition between healthy and cancer serum, which leaves the disease-relevant differences buried in noise and in the natural biological variation from one patient to the next.

We've published work in Research (a Science Partner Journal) on a dual-modal "search-and-confirm" approach to glioblastoma surgery that pairs indocyanine green (ICG) fluorescence with label-free Raman spectroscopy. ICG is widely used to highlight tumor tissue intraoperatively, but it accumulates wherever vascular boundaries are disrupted, which leads to signal outside the tumor and a systematic overestimate of the tumor boundary, risking resection of healthy brain tissue. Raman spectroscopy reads molecular composition directly and matches the true margin, but it's too slow to survey an open surgical field point by point.